EGFR and non-small cell lung carcinoma: One NSCLC patient with SD lasting ≥ 6 months, and who had a mutation in EGFR had progressed after 15-month gefitinib treatment; he then subsequently developed a T790M mutation which was defined prior to entry to this study.